# Possible link between the apparently pathogenic FANCI variant and beneficial effects in sports performance

**Authors:** Mariusz Berdyński, Małgorzata Borczyk, Kinga Humińska-Lisowska, Michał Korostyński, Paweł Cięszczyk, Cezary Żekanowski

PMC · DOI: 10.3389/fgene.2026.1745694 · Frontiers in Genetics · 2026-02-09

## TL;DR

A potentially harmful gene variant linked to DNA repair may help some athletes perform better, suggesting genetic mutations can have unexpected benefits.

## Contribution

The study identifies a rare FANCI gene variant in top athletes, suggesting a possible link between a pathogenic mutation and enhanced sports performance.

## Key findings

- A rare FANCI variant (rs121918164, R1285*) was found in three top-elite athletes but not in non-athletes or national-elite athletes.
- The variant is predicted to be damaging but may confer a performance advantage under certain conditions.
- Further research is needed to validate the potential beneficial effects of this variant in sports performance.

## Abstract

Athletic performance is a multifactorial trait influenced by both genetic and environmental factors. Evolutionary pressure can lead to seemingly contradictory effects of genetic mutations, and carriers of deleterious mutations may exhibit advantages. The objective of our exploratory study was to identify rare deleterious variants influencing athletic success. A total of 101 top-elite Polish athletes were recruited for the whole-genome sequencing analysis. We identified a variant in the FANCI gene (rs121918164, R1285*) in three unrelated top-elite athletes. This variant was absent in a large group of subjects from the same population: the national-elite athletes group (n = 890) who presented a lower level of sporting success and non-athletes (n = 1,009). Although, the R1285* FANCI variant is predicted to be damaging, we hypothesize that under certain conditions its carriers may have gained an advantage that facilitates success in sports. However, due to the limitations of the study, our observations require further investigation and validation in a larger and more diverse study groups.

## Linked entities

- **Genes:** FANCI (FA complementation group I) [NCBI Gene 55215]

## Full-text entities

- **Genes:** RAD51C (RAD51 paralog C) [NCBI Gene 5889] {aka BROVCA3, FANCO, R51H3, RAD51L2}, PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728] {aka BROVCA5, FANCN, PNCA3}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, ERCC4 (ERCC excision repair 4, endonuclease catalytic subunit) [NCBI Gene 2072] {aka ERCC11, FANCQ, RAD1, XFEPS, XPF}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, RFWD3 (ring finger and WD repeat domain 3) [NCBI Gene 55159] {aka FANCW, RNF201}, FANCM (FA complementation group M) [NCBI Gene 57697] {aka FAAP250, KIAA1596, POF15, SPGF28}, FAAP100 (FA core complex associated protein 100) [NCBI Gene 80233] {aka C17orf70, FANCX}, FANCD2 (FA complementation group D2) [NCBI Gene 2177] {aka FA-D2, FA4, FACD, FAD, FAD2, FANCD}, SLX4 (SLX4 structure-specific endonuclease subunit) [NCBI Gene 84464] {aka BTBD12, FANCP, MUS312}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, PRKDC (protein kinase, DNA-activated, catalytic subunit) [NCBI Gene 5591] {aka DNA-PKC, DNA-PKcs, DNAPK, DNAPKc, DNPK1, HYRC}, EPOR (erythropoietin receptor) [NCBI Gene 2057] {aka EPO-R}, FANCI (FA complementation group I) [NCBI Gene 55215] {aka KIAA1794}, CCR5 (C-C motif chemokine receptor 5) [NCBI Gene 1234] {aka CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, FANCA (FA complementation group A) [NCBI Gene 2175] {aka FA, FA-H, FA1, FAA, FACA, FAH}, BRIP1 (BRCA1 interacting DNA helicase 1) [NCBI Gene 83990] {aka BACH1, FANCJ, OF}, FAAP24 (FA core complex associated protein 24) [NCBI Gene 91442] {aka C19orf40}
- **Diseases:** acute myeloid leukemia (MESH:D015470), malaria (MESH:D008288), HIV resistance (MESH:D015658), FA (MESH:D005199), breast cancer (MESH:D001943), phenylketonuria (MESH:D010661), sickle-cell anemia (MESH:D000755), autosomal dominant erythrocytosis (MESH:C536842), cancer (MESH:D009369), LoF (MESH:D006315), autosomal recessive or X-linked disorder (MESH:D040181), defective hematopoiesis (MESH:C536227), anemia (MESH:D000740), monogenic diseases (MESH:D004194), congenital anomalies (MESH:D000013), hereditary breast and/or ovarian cancer (MESH:D061325)
- **Chemicals:** MMC (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Arg1285Gln, rs1049434, rs974948748, rs750419590, c.3853C>T
- **Cell lines:** BD0952 — Homo sapiens (Human), Fanconi anemia, complementation group I, Transformed cell line (CVCL_GR83)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12925683/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12925683/full.md

---
Source: https://tomesphere.com/paper/PMC12925683